At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CADL Candel Therapeutics, Inc.
Post-Market Trading 01-08 19:40:35 EST
8.73
+0.38
+4.55%
盘后8.65
-0.08-0.92%
19:37 EST
High8.77
Low7.95
Vol1.50M
Open8.30
D1 Closing8.35
Amplitude9.76%
Mkt Cap370.81M
Tradable Cap272.00M
Total Shares42.48M
T/O12.55M
T/O Rate4.80%
Tradable Shares31.16M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Candel Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $19 From $11
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.